問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

5163Cases

2014-06-30 - 2017-06-30

Phase III

Mepolizumab vs. Placebo as add-on treatment for frequently exacerbating COPD patients characterized by eosinophil level

  • Condition/Disease

    COPD

  • Test Drug

    Mepolizumab

Participate Sites
5Sites

Terminated4Sites

Study ended1Sites

徐武輝
China Medical University Hospital

Division of General Internal Medicine

2014-07-01 - 2017-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2023-07-01 - 2026-07-01

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2021-06-01 - 2023-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2019-12-01 - 2022-12-31

Phase I

A Phase I Open-Label Study of the Safety and Tolerability of ATG-019, a Dual Inhibitor of PAK4 and NAMPT, in patients with Advanced Solid Tumors or Non-Hodgkin's Lymphoma.

  • Condition/Disease

    Solid Tumor/Non-Hodgkin's Lymphoma

  • Test Drug

    ATG-019

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

2019-08-20 - 2021-08-02

Phase I

A phase I, open label study to evaluate the safety and to explore efficacy of allogeneic umbilical cord mesenchymal stem cells in patients with ST-elevation acute myocardial infarction

  • Condition/Disease

    Acute Myocardial Infarction

  • Test Drug

    UMSC01

Participate Sites
1Sites

Recruiting1Sites

蕭連城
China Medical University Hospital

Division of Cardiovascular Diseases

2019-03-01 - 2021-12-31

Phase I

A Phase I Dose Escalation Study, With Cohort Expansion, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AbGn-107 Therapy in Patients With Chemo-refractory Locally Advanced, Recurrent, or Metastatic Gastric, Colorectal, Pancreatic or Biliary Cancer

  • Condition/Disease

    Gastric, Colorectal, Pancreatic or Biliary Cancer

  • Test Drug

    AbGn-107

Participate Sites
3Sites

Terminated3Sites

2022-03-01 - 2022-09-30

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2014-11-01 - 2019-03-31

Phase III

ONO-4538 Phase III Study A Multicenter, Double-Blind, Randomized Study in Patients with Unresectable Advanced or Recurrent Gastric Cancer

  • Condition/Disease

    Unresectable Advanced or Recurrent Gastric Cancer

  • Test Drug

    ONO-4538

Participate Sites
9Sites

Terminated9Sites

2014-03-01 - 2019-01-31

Phase III

A phase III, placebo-controlled, multi-center, randomized, double-blind trial to evaluate the efficacy and safety of K-333 (peretinoin) in patients with complete cure of hepatocellular carcinoma in Asia

  • Condition/Disease

    hepatocellular carcinoma

  • Test Drug

    K-333

Participate Sites
17Sites

Terminated16Sites

Study ended1Sites

鄭隆賓
China Medical University Hospital

1 502 503 504 505 506 517
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB